Calamos Wealth Management LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

Calamos Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 17.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,764 shares of the company’s stock after purchasing an additional 3,351 shares during the quarter. Calamos Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,581,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. M. Kulyk & Associates LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock valued at $274,000 after acquiring an additional 119 shares during the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in shares of Novo Nordisk A/S by 0.4% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 31,494 shares of the company’s stock worth $2,709,000 after purchasing an additional 136 shares during the period. BIP Wealth LLC increased its holdings in Novo Nordisk A/S by 3.9% in the 4th quarter. BIP Wealth LLC now owns 3,642 shares of the company’s stock valued at $313,000 after purchasing an additional 138 shares during the last quarter. Xponance Inc. raised its position in Novo Nordisk A/S by 4.9% in the fourth quarter. Xponance Inc. now owns 3,156 shares of the company’s stock valued at $271,000 after purchasing an additional 146 shares during the period. Finally, Mystic Asset Management Inc. raised its position in Novo Nordisk A/S by 1.2% in the fourth quarter. Mystic Asset Management Inc. now owns 13,185 shares of the company’s stock valued at $1,134,000 after purchasing an additional 150 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NVO shares. BMO Capital Markets reaffirmed a “market perform” rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Price Performance

NVO stock opened at $69.05 on Friday. The business’s 50-day moving average is $69.82 and its two-hundred day moving average is $76.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm has a market capitalization of $308.31 billion, a P/E ratio of 20.43, a P/E/G ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $143.69.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion for the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.